This study was designed to evaluate the efficacy of combination treatment of pemetrexed
plus oxaliplatin as second-line treatment in advanced/metastatic non-small cell lung cancer …

7133 Background: Results from a large, randomized, phase III study of pemetrexed vs
docetaxel as second-line treatment for advanced NSCLC indicated that pemetrexed, a novel …

7601 Background: Pemetrexed in combination with carboplatin has been shown to have
promising activity and favorable toxicity profile in NSCLC. Bevacizumab has been shown to …

Aim: We conducted a phase II study to evaluate the efficacy and safety of pemetrexed
continuation-maintenance after carboplatin-based induction for advanced non-squamous …

7074 Background: P (Alimta), a multitargeted antifolate, inhibits thymidylate synthase,
dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. P and cisplatin …

Background and objective Since the poor outcome for advanced lung cancer with first-line
chemotherapy, more efforts should be paid for treatment of advanced recurrent or metastasis …

Background To evaluate the efficacy and safety of pemetrexed therapy for chemotherapy-
naïve patients with surgically incurable non-small-cell lung cancer (NSCLC). Patients and …

BACKGROUND: We sought to identify the relationship between response to previous
systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non …

Background The efficacy of pemetrexed in the second-line treatment of Chinese patients
with advanced non-small cell lung cancer (NSCLC) has been shown to be similar to that of …

Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment
of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of …